Valuation: AstraZeneca PLC

Market Cap 262B 231B 214B 197B 369B 25,315B 376B 2,546B 994B 12,409B 984B 963B 42,944B P/E 2026 *
21.1x
P/E 2027 * 18.5x
Enterprise Value 281B 248B 230B 211B 397B 27,168B 403B 2,733B 1,067B 13,318B 1,056B 1,033B 46,088B EV / Sales 2026 *
4.45x
EV / Sales 2027 * 4.1x
Free-Float
96.63%
Yield 2026 *
1.98%
Yield 2027 * 2.08%

Last Transcript: AstraZeneca PLC

Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-.--% - - 262B
+0.86%+2.30%+49.71%+158.86% 1,057B
+1.59%+5.37%+55.77%+54.77% 624B
+0.95%+1.95%+36.11%+80.44% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.60%+2.95%+36.28%+39.04% 297B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+1.20%+21.61%+60.14% 201B
-1.18%-5.13%+13.87%+60.35% 162B
-0.16%-2.39%-3.23%-34.39% 143B
Average -0.61%+0.66%+24.27%+45.15% 388.29B
Weighted average by Cap. -0.39%+1.56%+36.33%+76.73%

Financials

2026 *2027 *
Net sales 63.21B 55.6B 51.68B 47.45B 89.07B 6,103B 90.56B 614B 240B 2,991B 237B 232B 10,352B 66.78B 58.75B 54.6B 50.14B 94.1B 6,447B 95.68B 649B 253B 3,160B 251B 245B 10,937B
Net income 12.43B 10.94B 10.16B 9.33B 17.52B 1,200B 17.81B 121B 47.14B 588B 46.66B 45.66B 2,036B 13.93B 12.25B 11.39B 10.46B 19.63B 1,345B 19.96B 135B 52.82B 659B 52.28B 51.16B 2,281B
Net Debt 19.2B 16.89B 15.7B 14.41B 27.05B 1,853B 27.5B 186B 72.79B 908B 72.05B 70.5B 3,144B 11.9B 10.47B 9.73B 8.94B 16.77B 1,149B 17.06B 116B 45.14B 563B 44.68B 43.72B 1,950B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
169.04USD
Average target price
212.16USD
Spread / Average Target
+25.51%

Quarterly revenue - Rate of surprise